BST2 and melanoma: By analyzing the TCGA genomics data of SEL1L3, HAPLN3, BST2, and IFITM1, we found that the gene alteration rates in melanoma were 10% for SEL1L3, 4% for HAPLN3, 0.8% for BST2, and 0.6% for IFITM1 (Fig. 6a), and these alterations were not recurrent.